Vanda Pharmaceuticals (VNDA) Invested Capital (2009 - 2026)

Vanda Pharmaceuticals' Invested Capital history runs 18 years deep, the most recent figure standing at $280.8 million for Q1 2026.

• In Q1 2026, Invested Capital fell 45.1% year-over-year to $280.8 million; the TTM figure through Mar 2026 stood at $280.8 million (down 45.1% YoY), while the FY2025 annual figure was $334.7 million, down 38.42% from the prior year.
• Invested Capital came in at $280.8 million for Q1 2026 at Vanda Pharmaceuticals, down from $334.7 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $544.9 million in Q4 2023 to a low of $280.8 million in Q1 2026.
• A 5-year average of $498.1 million and a median of $527.2 million in 2022 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital climbed 7.38% in 2022 and slumped 45.1% in 2026, its largest moves.
• Vanda Pharmaceuticals' Invested Capital stood at $527.2 million in 2022, then gained by 3.36% to $544.9 million in 2023, then fell by 0.26% to $543.5 million in 2024, then tumbled by 38.42% to $334.7 million in 2025, then retreated by 16.11% to $280.8 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $280.8 million, $334.7 million, and $466.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison